Skip navigation

Healthcare, Pharma & Biotech Team

Chris Winter

Photo Chris is a Resident Business Builder at AcceleratorIndia, where his primary focus is on businesses in the Healthcare & MedTech sectors.

He has a unique technology and business background that spans large corporations, start-ups, incubators, venture capital and public sector organizations.

Chris is currently Chairman of Health Enterprise East, one of the NHS innovation hubs, and non-executive director of Regenersys, a medical service company. Previously, he worked for BT in key scientific and engineering roles, was on the board of a computer games company, co-founded as CTO BT’s corporate incubator and has spent the last ten years as Partner in a transatlantic venture firm.

Chris has been involved in building or investing in around 40 start-ups and spin-outs from major corporations round the world. He specializes in identifying the potential in early stage technologies and understanding how to take them to market. He is also involved in providing consultancy on innovation to major corporations in the medical, energy, telecoms and business service industries.

He teaches occasionally at the Judge Business School at Cambridge, and is a visiting professor at the University Campus of Suffolk, Brunel University and Reading University.

Chris read Biochemistry at Oxford University, followed by a PhD in Physics at Lancaster University and an 1852 Research Fellowship. A curious achievement was to get quoted in Arthur C. Clarke’s book “3001” for a prediction on chip technology.

Mary Anne Cordeiro

PhotoMary Anne Cordeiro is very active as an advisor to innovative companies in the healthcare sector. Her current clients include a number of device, diagnostic, orthopaedic, drug delivery and therapeutic businesses which require advice on business and funding strategy. She has also evaluated new technologies that address important healthcare needs for the large and growing Indian market and has cultivated a network of practitioners, industry experts and a network of investors in Asia and Europe. She herself is an active business angel investor and regularly reviews investment opportunities for two groups of Oxford and London-based angel networks.

Mary Anne is a Non-Executive Director of Albion Income & Growth VCT PLC ("Albion VCT") where she is one of five board members responsible for overseeing the investment strategy of Albion VCT and the performance of the investment manager, Albion Ventures LLP. This gives her a unique insight into the issues associated with early stage technology investment and the features that venture capital investors seek when structuring deals. She was instrumental in closing the agreement with Albion VCT where part of the £45 million raised was ear-marked for technology businesses from Brunel University, St George’s Hospital and University College London.

Mary Anne has a unique combination of skills, experience and alliances to assist the boards of SMEs to develop into global businesses. Since 1998, she has been working on the commercialisation of innovation and has helped develop strategies to bring new products and services to market as well as to finance growth. Furthermore, Mary Anne’s fifteen-year career in the City (1983-1998) with Goldman Sachs, Bankers Trust and Paribas has given her extensive expertise in all aspects of corporate finance including: valuation methodologies; M&A transaction structure, negotiation and closure; as well as access to a broad network of professional investors.

She graduated with an MA Honours (Oxon) degree in Chemistry, completed a dissertation in Quantum Pharmacology under Professor Graham Richards and was awarded an open scholarship to Worcester College, Oxford University to read Chemistry.

Richard Cawdell

Photo Richard has broad international business background in consultancy, telecommunications, and information systems, and has experience of technology enabled innovation in sectors ranging from healthcare, through media, retail, financial services, manufacturing and culture.

He has an extensive background in implementation and execution, including addressing systems, infrastructure, technology, security and IS governance issues in financial services in the City of London, firstly as Group I.T. Director of Exco (now Intercapital), and latterly responsible for technology within the Rothschild merchant bank.

His early career included market and product focused roles in high growth technology companies as well as consideration of the long term potential of communications technologies for BT. He was exposed to the brand led cultures of Grand Metropolitan (now Diageo) and Allied Signal, and the early development of technology R&D policy for broadband communications technologies and applications at the European Commission.

Richard has maintained focus throughout his career on innovation and the stimulation and management of change. He graduated from the University of Sussex with a degree in Physics and Mathematics.

Jan Buch Andersen

Photo Jan is a serial entrepreneur involved with numerous start-ups in the field of biotech. He is a native Dane, and did his Ph.D. at the University of Copenhagen in plant molecular biology.

After leaving academia, he built a distribution company specialized in molecular biology/cell culture reagents in Denmark. After selling it to Fisher Scientific in 2002, he had Sales Manager tenures with Invitrogen and Roche Diagnostics, before moving on to co-found InMold Biosystems, a company in the advanced laboratory plastics area allowing to mould functional proteins into plastic surfaces. After that he spent a year living in India and working for Bangalore Genei, leaving the company, as it was sold to Merck Millipore, for a position as Managing Director of ArcticZymes in Tromsø, Northern Norway. While based in Tromsø, Jan also founded Barentzymes in 2014 – a company developing enzymes for the industrial biotechnology area using a brand new bioinformatics based approach. After exiting Barentzymes earlier this year, Jan is now in the planning phase for a new venture in the biotech field.

Over the years Jan has acquired a solid commercial network, and a deep understanding of what it takes to do business throughout the world. He is commercial in all he does, and knows every aspect of building a business from the scientific core to running day to day business motivating highly skilled employees. Jan has experience reporting for stock market listed companies, and has been running companies with multi-country offices. He has delivered outstanding results leading turn‐around processes at troubled companies.

Jan is the chairman for the Industrial Biotech Network Norway that added substantially to his international network in the developing bioeconomy stage. He is furthermore on the program board for the largest biotechnology program (Biotek2021) at the Norwegian Research Council and has been invited speaker at a number of international conferences including two of BIO´s Industrial Biotech conferences.

Last updated: 16 Jan 2017